Study on the Mechanism of Liuwei Dihuang Pill s Formula in Treating Parkinson's Disease Based on Network Pharmacology

Abstract

Abstract Background: Parkinson's Disease (PD) is a common neurodegenerative disease in middle-aged and elderly people. Liuwei Dihuang Pill (LWDH Pills) has good effect on Parkinson's disease but the mechanism of action is not clear. Network pharmacology is the result of integrating the basic theories and research methods of medicine, biology, computer science, bioinformatics and other disciplines, which can systematically and comprehensively reflect the mechanism of drug intervention in disease network.Methods: Obtained the main components and targets of herbs in LWDH Pills through Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database, and screen the active components of traditional Chinese medicine according to ADME; The PD-related targets were obtained from Gencards, OMIM, TTD, DRUGBANK databases. Used Jvenn to take the intersection of targets of LWDH Pills and PD-related targets, use the String platform to analyze protein interactions, construct a PPI network and explore potential protein functional modules in the network. The Metascape platform was used to performe KEGG pathway and GO Function enrichment analysis. Finally, the Cytoscape software was used to construct the drug-components-target network.Results: After screening and de-weighting, 210 effective active ingredients of LWDH Pills, 204 drug targets, 4333 diabetic nephropathy disease targets, and 162 drug-disease targets were obtained by the intersection of Jvenn. GO and KEGG enrichment analysis showed that these targets are involved in neuron death, G protein-coupled amine receptor activity, reactive oxygen species metabolic process, membrane raft, MAPK signaling pathway, cellular senescence and other biological processes. Drug-components-target shows that the hub components of Liuwei Dihuang Pills were quercetin, Stigmasterol, kaempferol, and beta-sitosterolConclusion: LWDH Pill has the characteristics of multi-component, multi-target and multi-pathway for the treatment of PD. The hub components may be quercetin, Stigmasterol, kaempferol, and beta-sitosterol, and may be through pairing hub targets such as AKT1, VEGFA, IL6, etc. to regulate Neuron death, G protein-coupled amine receptor activity, reactive oxygen species metabolic process, membrane raft, MAPK signaling pathway, cellular senescence to play a role in the treatment of PD